This paper is in the following e-collection/theme issue:

Reviews on Public Health Technology and Innovation (86) Prevention and Health Promotion (1423) Pharmacovigilance (177) HIV/AIDS/STI Prevention and Care (1061)

Published on in Vol 9 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/46767, first published .
Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis

Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis

Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis

Authors of this article:

Wenjing Wang1 Author Orcid Image ;   Shengnan Zhao1 Author Orcid Image ;   Yaxin Wu1 Author Orcid Image ;   Wenshan Duan1 Author Orcid Image ;   Sibo Li1 Author Orcid Image ;   Zhen Li2 Author Orcid Image ;   Caiping Guo1 Author Orcid Image ;   Wen Wang1 Author Orcid Image ;   Tong Zhang1 Author Orcid Image ;   Hao Wu1 Author Orcid Image ;   Xiaojie Huang1 Author Orcid Image
Article Authors Cited by (24) Tweetations (2) Metrics

Journals

  1. Ramarao B, Kamalakaran A. A selective, sensitive and fast LC–MS/MS method for cabotegravir quantification in rat plasma and pharmacokinetic investigations. Biomedical Chromatography 2024;38(11) View
  2. Scott G, Worku D. HIV vaccination: Navigating the path to a transformative breakthrough—A review of current evidence. Health Science Reports 2024;7(9) View
  3. Hu T, Yang S, Yu J, Yang Z, Jin Y, Zhu Z. Transitions in treatment: A systematic review and meta‐aggregation of preferences and barriers in switching from oral to long‐acting injectable antiretroviral therapy among people living with HIV and stakeholders. HIV Medicine 2025;26(4):512 View
  4. Manalu S, Perez Navarro A, Fairhead C, Hill A. Safety and efficacy of long-acting cabotegravir/rilpivirine versus standard oral antiretroviral therapy: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy 2025;80(3):624 View
  5. Mchantaf G, Chaillon A, Charre C, Melard A, Gardiennet E, Guinard J, Prazuck T, Guillaume C, Mariaggi A, Bois J, Hocqueloux L, Avettand-Fenoel V. Learning From Full Characterization of HIV Proviruses in People Receiving Long-Acting Cabotegravir/Rilpivirine With a History of Replication on the Antiretroviral Classes. Open Forum Infectious Diseases 2024;12(1) View
  6. Lanzafame M, Mori G, Vento S. Advances in HIV Treatment: Long-Acting Antiretrovirals and the Path Toward a Cure. Biomedicines 2025;13(2):493 View
  7. Mahomed S, Pillay K, Hassan-Moosa R, Galvão B, Burgers W, Moore P, Rose-Abrahams M, Williamson C, Garrett N. Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review. AIDS Research and Therapy 2025;22(1) View
  8. Johnson J, Brotherton A, Rossi M, Sanchez M, Beckwith C. Long-Acting Injectable Antiretroviral Therapy for Treatment of Human Immunodeficiency Virus: A Review. Current HIV/AIDS Reports 2025;22(1) View
  9. Xie X, Fu Y, Gan L, Yang X, Song Y, Song C, Sun F, Guo L, Long H. Safety and efficacy of switching to 4-weekly albuvirtide plus daily dolutegravir in virologically suppressed HIV-1 adults: a 24-week study. AIDS 2025;39(7):857 View
  10. Sheehan D, Ramírez-Ortiz D, Gwanzura T, Lewis P, Ertl M, Duncan D, Swendeman D, Muñoz-Laboy M, Devieux J, Trepka M. Daily Factors Associated with Antiretroviral Therapy Adherence Among Young Latino Sexual Minority Men with HIV: A 28-Day Daily Diary Study. AIDS and Behavior 2025;29(10):3054 View
  11. Rashid I, Unger N, Willis C, Dhippayom T, Ramgopal M, Sherman E, Yared N, Safran R, Swiatlo E, Weinberg A, Navadeh S, Schmutz H, Chaiyakunapruk N. Comparison of treatment‐emergent resistance‐associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor‐based single‐tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta‐analysis. HIV Medicine 2025;26(8):1184 View
  12. Aidoo-Frimpong G, Koku E, Okoro O, Gyamerah A, Johnson N, Schwartz S. Sankofa! Leveraging Cultural Assets to Advance Long-Acting Injectable Pre-exposure Prophylaxis Among U.S.-Based African Immigrants. Journal of Immigrant and Minority Health 2025;27(5):652 View
  13. Bottanelli M, Castagna A, Muccini C. Safety, Tolerability, and Metabolic Effects of Long-Acting Cabotegravir and Rilpivirine in HIV Care: A Comprehensive Review. Viruses 2025;17(8):1108 View
  14. Moreno A, Fernandez-Ibanez R, Del Campo S, Perez-Elias M, Casado J, Garcia M, Velez M, Vivancos M, Moreno S. Long-Acting Cabotegravir and Rilpivirine in Patients With HIV With Solid Organ Transplantation: A Case Series. Open Forum Infectious Diseases 2025;12(8) View
  15. Palomares M, Shade S, Pollack L, Zand P, Bourdeau B, Moore E, Bolton A, Van Nuys J, Johnson M, Rebchook G, Saberi P. Enthusiasm for Participation in a Novel, At-Home Delivery Model for Injectable HIV Treatment Among People With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 2025;100(3):e14 View
  16. Conti G, Spampinato S, De Vito A, Marino A, Cirelli T, Coco V, Mirabile A, Fontana del Vecchio R, Franco A, Montineri A, Fasca C, Gullotta C, Paternò Raddusa M, Russotto Y, Sofia S, Pantò G, Calì C, Bruno R, Pistarà E, Villari N, Iacobello C, Cacopardo B, Celesia B, Pellicanò G, Antonucci F, Lo Caputo S, Madeddu G, Nunnari G, Venanzi Rullo E. Efficacy and Safety of Cabotegravir–Rilpivirine in PLWH: A Real-World Study. Viruses 2025;17(11):1417 View
  17. Soulie C, Agher R, Fauchois A, Abdi B, Wirden M, Teyssou E, Sayon S, Katlama C, Valantin M, Tubiana R, Schneider L, Faycal A, Palich R, Pourcher V, Marcelin A, Calvez V. Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable. Journal of Antimicrobial Chemotherapy 2026;81(1) View
  18. Su S, Wei Y, Dong W, Sun J, Li Y, Zhang W, Song Q, Wu Z, Zhao R, Zhang L. Epidemiological impacts and cost-effectiveness of daily and on-demand oral pre-exposure prophylaxis among key HIV populations in China: An economic evaluation. Epidemiology and Infection 2025;153 View
  19. Oo M, Arulananthan A, Wijesinghe A, Sanh M, Tan D. Using a paper-based checklist for promoting increased access to long-acting injectable cabotegravir/rilpivirine among people living with HIV in Toronto: Lessons learned from a quality improvement initiative. Journal of the Association of Medical Microbiology and Infectious Disease Canada 2025;10(4):310 View
  20. Wang S, Ma F, Lindsley C, Xu S, Liu X, Zhan P. Recent Advances in Long-Acting Antiviral Agents: Innovations in Design and Strategies for Extended Duration. Journal of Medicinal Chemistry 2025 View
  21. Sisteré-Oró M, Güerri-Fernandez R, Plana M, Bocharov G, Meyerhans A. Challenges in the Vaccination of HIV-Infected Individuals. Vaccines 2025;14(1):40 View
  22. Cao T, Chen X, Chen H, Lu X, Li Y, Gao H, Hou C, Gao J. Preferences for long‐acting antiretroviral therapy among people with HIV: A systematic review of discrete choice experiments. HIV Medicine 2026 View
  23. Dolatto Milléo L, Muller E, Martins C, Massalaka Rublesperger A, Ribas V, Silva G. Evidence for the efficacy and safety of pre-exposure prophylaxis (PrEP) in all populations: a systematic review and meta-analysis. AIDS Care 2026:1 View

Books/Policy Documents

  1. . The Maudsley Prescribing Guidelines in Psychiatry. View